Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.

about

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.

P2860

Q47095186-CF8AE3A9-37BD-4B37-9289-261220DCB02E Q49715387-8FF561EA-4BA2-4BB1-B1C2-4B73849703CA

P2860

Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.

Item

http://www.wikidata.org/entity/Q46320593

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Dapagliflozin slows the progre ...... sociated with type 2 diabetes.

@en

Dapagliflozin slows the progre ...... sociated with type 2 diabetes.

@nl

type

Item

label

Dapagliflozin slows the progre ...... sociated with type 2 diabetes.

@en

Dapagliflozin slows the progre ...... sociated with type 2 diabetes.

@nl

prefLabel

Dapagliflozin slows the progre ...... sociated with type 2 diabetes.

@en

Dapagliflozin slows the progre ...... sociated with type 2 diabetes.

@nl

P1476

Dapagliflozin slows the progre ...... sociated with type 2 diabetes.

@en

P2093

C David Sjöström

http://www.w3.org/2001/XMLSchema#string

David M Smith

http://www.w3.org/2001/XMLSchema#string

Li Tang

http://www.w3.org/2001/XMLSchema#string

Mi Tian

http://www.w3.org/2001/XMLSchema#string

Ulrika Johansson

http://www.w3.org/2001/XMLSchema#string

Xiao-Rong Peng

http://www.w3.org/2001/XMLSchema#string

Yuanyuan Wu

http://www.w3.org/2001/XMLSchema#string

Yufeng Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Renal effects of dapagliflozin in patients with type 2 diabetes

Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation

Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus

Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome

Myeloperoxidase: friend and foe

Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments

A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes

Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver.

Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.

Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.

P304

E563-E576

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPENDO.00086.2017

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

313

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28811292

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.

about

P2860

P2860

Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921